BSTFA-TMCS is used as a derivatizing agent in chromatography. It functions as a silylation reagent without additional solvents. The combination of BSTFA and TMCS is the preferred reagent for trimethylsilylation of alcohols, alkaloids, amines, biogenic amines, carboxylic acids, phenols, and steroids.

BTB-1 is a novel, selective and reversible inhibitor of the mitotic motor protein Kif18A with IC50 of 1.69 μM.

BTB-1 is a novel, selective and reversible inhibitor of the mitotic motor protein Kif18A with IC50 of 1.69 μM.

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase.

BTdCPU is a potent activator of heme regulated inhibitor kinase (HRI), one of eukaryotic translation initiation factor 2α kinases (eIF2α-kinases).

BTdCPU is a potent activator of heme regulated inhibitor kinase (HRI), one of eukaryotic translation initiation factor 2α kinases (eIF2α-kinases).

BTK IN-1(SNS062 analog) is a potent Bruton’s tyrosine kinase (BTK) inhibitor, with an IC50 of

BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.

Btk inhibitor 2 is a BTK inhibitor.

BTR-1 induces cytotoxicity in a time- and concentration-dependent manner on leukemia cell line CEM. BTR-1 affects DNA replication by inducing a block at S phase and leads to activation of apoptosis to induce cell death.

BTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.

BTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1) inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis.

BTZO-1 binds to macrophage migration inhibitory factor (MIF) with Kd of 68.6 nM. BTZO-1 activats antioxidant response element (ARE)-mediated gene expression and suppresses oxidative stress-induced cardiomyocyte apoptosis in vitro.

Bucetin is an analgesic and antipyretice agent with a risk of carcinogenesis.

Buddlejasaponin IVb (Saikosaponin 1b), a major component of Pleurospermum kamtschaticum, exerts anti-inflammatory and cytotoxic effects against cancer cells.

Budesonide(Labazenit) is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis.

Budesonide(Labazenit) is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis.

Bufalin (BF) is a potent inhibitor of steroid receptor coactivator SRC-3, SRC-1 and Na+/K+-ATPase. Bufalin binds to the subunit α1, α2 and α3 of Na+/K+-ATPase with Kd of 42.5 nM, 45 nM and 40 nM, respectively. Bufalin is a major digoxin-like immunoreactive component isolated from the Chinese medicine Chan Su with anti-cancer activity.

Bufalin (BF) is a potent inhibitor of steroid receptor coactivator SRC-3, SRC-1 and Na+/K+-ATPase. Bufalin binds to the subunit α1, α2 and α3 of Na+/K+-ATPase with Kd of 42.5 nM, 45 nM and 40 nM, respectively. Bufalin is a major digoxin-like immunoreactive component isolated from the Chinese medicine Chan Su with anti-cancer activity.

Bufalin (BF) is a potent inhibitor of steroid receptor coactivator SRC-3, SRC-1 and Na+/K+-ATPase. Bufalin binds to the subunit α1, α2 and α3 of Na+/K+-ATPase with Kd of 42.5 nM, 45 nM and 40 nM, respectively. Bufalin is a major digoxin-like immunoreactive component isolated from the Chinese medicine Chan Su with anti-cancer activity.

Bufexamac(Bufexamic acid) is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Bulleyaconi cine A (Bulleyaconitine A, BLA) is an active ingredient of Aconitum bulleyanum plants and classified as an “aconitine-like” alkaloid. It is a potent use-dependent blocker for both Nav1.7 and Nav1.8 Na+ currents.

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. Bumetanide is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Buparvaquone (Butalex) is a second-generation hydroxynaphthoquinone related to parvaquone, with novel features that make it a promising compound for the therapy and prophylaxis of all forms of theileriosis.